98 results on '"Naso R"'
Search Results
2. EXPERIMENTAL IMMUNE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION: PASSIVE ANTI-HCV (HCIg) TRANSFER IN CHRONICALLY INFECTED CHIMPANZEES
- Author
-
Krawczynski, K., Fattom, A., Culver, D., Kamili, S., Spelbring, J., Basham, L., Sapan, C., Naso, R., Purdy, M., and Carson, D.
- Published
- 2000
3. EXPERIMENTAL TREATMENT OF HCV INFECTION: PASSIVE ANTI-HCV TRANSFER IN ACUTELY INFECTED CHIMPANZEES
- Author
-
Krawczynski, K., Fattom, A., Sapan, C., Naso, R., Spelbring, J., Kamili, S., Purdy, M., and Basham, L.
- Published
- 1999
4. Phenotypic and Genotypic Characterization of Nosocomial Staphylococcus aureus Isolates from Trauma Patients
- Author
-
Na'was, T., Hawwari, A., Hendrix, E., Hebden, J., Edelman, R., Martin, M., Campbell, W., Naso, R., Schwalbe, R., Fttom, A.I., Na'was, T., Hawwari, A., Hendrix, E., Hebden, J., Edelman, R., Martin, M., Campbell, W., Naso, R., Schwalbe, R., and Fttom, A.I.
- Abstract
Staphylococcus aureus is a major cause of nosocomial infections. During the period from March 1992 to March 1994, the patients admitted to the intensive care unit of the University of Maryland Shock Trauma Center were monitored for the development ofS. aureus infections. Among the 776 patients eligible for the study, 60 (7.7%) patients developed 65 incidents of nosocomialS. aureus infections. Of the clinical isolates, 43.1% possessed a polysaccharide type 5 capsule, 44.6% possessed a type 8 capsule, and the remaining 12.3% had capsules that were not typed by the type 5 or type 8 antibodies. Six antibiogram types were noted among the infection-related isolates, with the majority of the types being resistant only to penicillin and ampicillin. It was noted that the majority of cases of pneumonia were caused by relatively susceptible strains, while resistant strains were isolated from patients with bacteremia and other infections. Only 16 (6.3%) of the isolates were found to be methicillin-resistant S. aureus (MRSA). DNA fingerprinting by pulsed-field gel electrophoresis showed 36 different patterns, with characteristic patterns being found for MRSA strains and the strains with different capsular types. Clonal relationships were established, and the origins of the infection-related isolates in each patient were determined. We conclude that (i) nosocomial infection-related isolates from the shock trauma patients did not belong to a single clone, although the predominance of a methicillin-resistant genotype was noted, (ii) most infection-relatedS. aureus isolates were relatively susceptible to antibiotics, but a MRSA strain was endemic, and (iii) for practical purposes, the combination of the results of capsular and antibiogram typing can be used as a useful epidemiological marker.
- Published
- 2016
5. Variations in rat liver chromatin composition during growth and the heterotic response
- Author
-
Naso, R. B., Baker, F. T., Kaczmarczyk, W., and Ulrich, V.
- Published
- 1976
- Full Text
- View/download PDF
6. Biosynthesis of Murine Leukemia Virus Membrane Proteins and their Assembly into Virus Particles
- Author
-
ARLINGHAUS, R. B., primary, MURPHY, E. C., additional, NASO, R. B., additional, ARCEMENT, L. J., additional, and KARSHIN, W. L., additional
- Published
- 1978
- Full Text
- View/download PDF
7. Properties of Moloney Sarcoma Virus-Specific p60 and its Detection in Transformed Cells
- Author
-
Vande Woude, G. F., primary, Robey, W. G., additional, Oskarsson, M. K., additional, Haapala, D. K., additional, Fischinger, P. J., additional, Naso, R. B., additional, and Arlinghaus, R. B., additional
- Full Text
- View/download PDF
8. PI-46Pharmacokinetics (PK), safety, and pharmacodynamics (PD) of Hematide™, a synthetic peptide-based erythropoiesis stimulating agent (ESA), in a phase 1 single dose, dose escalating study in normal healthy volunteers (NHVS).
- Author
-
LAMBERT, J, primary, DULIEGE, A, additional, STEAD, R, additional, WESSELS, D, additional, PCIKUP, E, additional, IWASHITA, J, additional, LEUTHER, K, additional, WOODBURN, K, additional, SCHATZ, P, additional, and NASO, R, additional
- Published
- 2006
- Full Text
- View/download PDF
9. HCV molecular studiesin chronically infected chimpanzees treated with anti-HCV immunoglobulins
- Author
-
Krawczynski, K., primary, Kamili, S., additional, Li, X., additional, Abubaker, R., additional, Carson, D., additional, Fattom, A., additional, Naso, R., additional, and Spelbring, J., additional
- Published
- 2001
- Full Text
- View/download PDF
10. Experimental immune treatment of hepatitis C virus (HCV) infection:Passive anti-HCV (HCIg) transfer in chronically infected chimpanzees
- Author
-
Krawczynski, K., primary, Fattom, A., additional, Culver, D., additional, Kamili, S., additional, Spelbring, J., additional, Basham, L., additional, Sapan, C., additional, Naso, R., additional, Purdy, M., additional, and Carson, D., additional
- Published
- 2000
- Full Text
- View/download PDF
11. Phenotypic and Genotypic Characterization of Nosocomial Staphylococcus aureus Isolates from Trauma Patients
- Author
-
Na’was, T., primary, Hawwari, A., additional, Hendrix, E., additional, Hebden, J., additional, Edelman, R., additional, Martin, M., additional, Campbell, W., additional, Naso, R., additional, Schwalbe, R., additional, and Fattom, A. I., additional
- Published
- 1998
- Full Text
- View/download PDF
12. A Noncovalent Complex Vaccine Prepared with Detoxified Escherichia coli J5 (Rc Chemotype) Lipopolysaccharide and Neisseria meningitidis Group B Outer Membrane Protein Produces Protective Antibodies against Gram-Negative Bacteremia
- Author
-
Bhattacharjee, A. K., primary, Opal, S. M., additional, Taylor, R., additional, Naso, R., additional, Semenuk, M., additional, Zollinger, W. D., additional, Moran, E. E., additional, Young, L., additional, Hammack, C., additional, Sadoff, J. C., additional, and Cross, A. S., additional
- Published
- 1996
- Full Text
- View/download PDF
13. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge
- Author
-
Fattom, A I, primary, Sarwar, J, additional, Ortiz, A, additional, and Naso, R, additional
- Published
- 1996
- Full Text
- View/download PDF
14. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines
- Author
-
Robbins, J.B., Schneerson, R., Horwith, G., Naso, R., and Fattom, A.
- Abstract
Background: Staphylococcus aureus, the first or second most common pathogen isolated from patients, is capsulated; there are at least 12 capsular types, and types 5 and 8 comprise approximately 85% of blood. Types 5 and 8, composed of a trisaccharide repeat unit including a mannose uronic acid and 2 fucoses, are non-immunogenic. As protein conjugates, they induce opsonophagoctyic antibodies that confer type-specific active and passive protection in mice. Methods: A phase II study of patients with end-stage renal disease showed that these conjugates induced approximately one third of the immunoglobulin G antibody of healthy individuals. Increasing the dose to 100 @mg of polysaccharide induced levels similar to that in healthy individuals injected with 25 @mg. Results: In a double-blinded randomized and controlled study of patients undergoing renal dialysis, the conjugates induced statistically significant protection against bacteremia for as long as 10 months after immunization. The estimated protective level was 80 @mg Ab/mL. At re-injection approximately 2 years later, 83 of 83 recipients responded with protective levels. Conclusions: Conjugate vaccine-induced antibodies to the types 5 and 8 capsular polysaccharide antibodies of S aureus prevent bacteremia caused by this pathogen. The extent and duration of conjugate-induced immunity can be extended by re-immunization approximately 1 year later. Studies of patients undergoing cardiovascular surgery who would be immunized with the staphylococcus conjugates when they are immunologically intact are planned.
- Published
- 2004
- Full Text
- View/download PDF
15. Potent Inhibition of NTPase/Helicase of the West Nile Virus by Ring-Expanded (Fat) Nucleoside Analogues
- Author
-
Zhang, N., Chen, H.-M., Koch, V., Schmitz, H., Minczuk, M., Stepien, P., Fattom, A. I., Naso, R. B., Kalicharran, K., Borowski, P., and Hosmane, R. S.
- Abstract
A series of ring-expanded (fat) nucleoside analogues (RENs) containing the 6-aminoimidazo[4,5-e][1,3]diazepine-4,8-dione ring system have been synthesized and screened for inhibition of NTPase/helicase of the West Nile Virus (WNV). To assess the selectivity of RENs against the viral enzymes, a truncated form of human enzyme Suv3
( Δ 1 - 159) was also included in the study. Ring-expanded nucleosides16 ,17 , and19 , which possess the long C12 , C14 , and C18 side-chains, respectively, at position 6, as well as the ring-expanded heterocycle39 , which contains aralkyl substitution at position 1, were all found to have excellent profiles of activity and selectivity toward the viral versus human enzymes against the West Nile Virus (IC50 ranging 1−10 μM). Compound30 , while being an equally potent inhibitor of WNV, was found to be somewhat less selective, whereas compound36 , which is an α-anomeric counterpart of30 , exhibited potent and selective inhibition of WNV (IC50 1−3 μM). The same compounds that showed potent inhibition of viral helicase activity completely failed to show any activity against the viral NTPase reaction even up to 500 μM. However, at concentrations >500 μM of RENs and the ATP concentrations >10 times the Km value of the enzyme, a significant activation of NTPase activity was observed. This activating effect underwent further dramatic enhancement (>1000%) by further increases in ATP concentration in the reaction mixture, suggesting that the viral helicase and NTPase reactions are not coupled. A tentative mechanistic model has been proposed to explain the observed results.- Published
- 2003
16. Ring-Expanded (Fat) Nucleoside and Nucleotide Analogues Exhibit Potent in Vitro Activity against Flaviviridae NTPases/Helicases, Including Those of the West Nile Virus, Hepatitis C Virus, and Japanese Encephalitis Virus
- Author
-
Zhang, N., Chen, H.-M., Koch, V., Schmitz, H., Liao, C.-L., Bretner, M., Bhadti, V. S., Fattom, A. I., Naso, R. B., Hosmane, R. S., and Borowski, P.
- Abstract
A series of ring-expanded (fat) heterocycles, nucleoside and nucleotide analogues (RENs) containing the imidazo[4,5-e][1,3]diazepine ring system (
9 ,14 ,15 ,18 ,24 -26 ,28 ,31 , and33 ) and imidazo[4,5-e][1,2,4]triazepine ring systems (30b ,30c ,32 , and34 ), have been synthesized as potential inhibitors of NTPases/helicases of Flaviviridae, including the West Nile virus (WNV), hepatitis C virus (HCV), and Japanese encephalitis virus (JEV). An amino-terminal truncated form of human enzyme Suv3( Δ 1 - 159) was also included in the study so as to assess the selectivity of RENs against the viral enzymes. The analogues of RENs included structural variations at position 1 of the heterocyclic base and contained changes in both the type of sugar moieties (ribo, 2-deoxyribo, and acyclic sugars) and the mode of attachment (α versus β anomeric configuration) of those sugars to the heterocyclic base. The target RENs were biochemically screened separately against the helicase and ATPase activities of the viral NTPases/helicases. A number of RENs inhibited the viral helicase activity with IC50 values that ranged in micromolar concentrations and exhibited differential selectivity between the viral enzymes. In view of the observed tight complex between some nucleosides and RNA and/or DNA substrates of a helicase, the mechanism of action of RENs might involve their interaction with the appropriate substrate through binding to the major or minor groove of the double helix. The REN-5-triphosphates, on the other hand, did not influence the above unwinding reaction, but instead exerted the inhibitory effect on the ATPase activity of the enzymes. The activity was found to be highly dependent upon the low concentration levels of the substrate ATP. At concentrations >500 μM of RENs and the ATP concentrations >10 times the Km value of the enzyme, a significant activation of NTPase activity was observed. This activating effect underwent further dramatic enhancement (>1000%) by further increases in ATP concentration in the reaction mixture. A tentative mechanistic model has been proposed to explain the observed results, which includes an additional allosteric binding site on the viral NTPases/helicases that can be occupied by nucleoside/nucleotide-type molecules such as RENs.- Published
- 2003
17. Novel ring-expanded nucleoside analogs exhibit potent and selective inhibition of hepatitis B virus replication in cultured human hepatoblastoma cells
- Author
-
Sood, R. K., Bhadti, V. S., Fattom, A. I., Naso, R. B., Korba, B. E., Kern, E. R., Chen, H. M., and Hosmane, R. S.
- Published
- 2002
- Full Text
- View/download PDF
18. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.
- Author
-
Fattom, A I, Sarwar, J, Basham, L, Ennifar, S, and Naso, R
- Abstract
Bacterial capsular polysaccharides (CP) are carbohydrate polymers comprised of repeating saccharide units. Several of these CP have side chains attached to their backbone structures. The side chains may include O-acetyl, phosphate, sialic acid, and other moieties. Those moieties represent the immunodominant epitopes and the most functional ones. The clinically significant Staphylococcus aureus type 5 CP (CP 5) and type 8 CP (CP 8) are comprised of a trisaccharide repeat unit with one O-acetyl group attached to each repeat unit. The immunogenicity of these CP and the functionality of antibodies to the backbone and the O-acetyl moieties were investigated. Immunization with the native CP conjugates (CP with 75% O-acetylation) elicited a high proportion of antibodies directed against the O-acetyl moiety. Nonetheless, all of the vaccinees produced antibodies to the backbone moieties as well. Conjugate vaccines made of de-O-acetylated CP elicited backbone antibodies only. Antibodies to both backbone and O-acetyl groups were found to be opsonic against S. aureus strains which varied in their O-acetyl content. Absorption studies with O-acetylated and de-O-acetylated CP showed that (i) native CP conjugates generated antibodies to both backbone and O-acetyl groups and (ii) O-acetylated isolates were opsonized by both populations of antibodies while the non-O-acetylated strains were predominantly opsonized by the backbone antibodies. These results suggest that S. aureus CP conjugate vaccines elicit multiple populations of antibodies with diverse specificities. Moreover, the antibodies of different specificities (backbone or O-acetyl) are all functional and efficient against the variations in bacterial CP that may occur among clinically significant S. aureus pathogenic isolates.
- Published
- 1998
19. Selective decrease in the rate of cleavage of an intracellular precursor to Rauscher leukemia virus p30 by treatment of infected cells with actinomycin D
- Author
-
Jamjoom, G A, Naso, R B, and Arlinghaus, R B
- Abstract
The cleavage of an intracellular 67,000- to 70,000-dalton precursor, termed Pr4 to Rauscher leukemia virus (RLV) p30 protein proceeded at a slower rate when virus-producing cells were treated with actinomycin D (AMD). Treatment with AMD also caused a slight accumulation of Pr4 in purified early virus particles produced by a cell line which usually produces virions that contain little Pr4. The cleavage of other intracellular viral precursor polypeptides was not affected by treatment with AMD. Treatment of infected cells with cycloheximide, on the other hand, allowed the cleavage of Pr4 to proceed at the usual rate for a short period of time before further cleavage was drastically slowed or prevented. The cleavage of several other viral precursor polypeptides was also inhibited by treatment with cycloheximide. Different lines of evidence suggest that the mechanism of action of AMD is not due to a possible indirect effect on protein synthesis. Thus, the rate of cleavage of Pr4 was not affected by the length of pretreatment with AMD between 1 to 8 h. In addition, the combined effect of AMD and cycloheximide, at their maximal inhibitory concentrations, was greater than the effect of either drug alone, indicating the involvement of two at least partially different mechanisms in the action of AMD and cycloheximide. Furthermore, AMD did not affect the pulse labeling of viral precursor polypeptides. These results suggest that the interaction with viral RNA, whose production is inhibited by AMD, accelerates the cleavage of Pr4 to p30 during virus assembly. A hypothetical model is presented to illustrate th possible advantages of having a step in virus assembly in which genomic RNA interacts with a precursor to capsid proteins before the cleavage of that precursor.
- Published
- 1976
- Full Text
- View/download PDF
20. Comparative analysis: intracellular precursor polyproteins of baboon endogenous retroviruses and human viral isolate HL23V
- Author
-
Whiteley, S A and Naso, R B
- Abstract
Intracellular precursor polyproteins of three baboon endogenous retrovirus (BaEV) isolates, m7, 455K, and BILN, were compared with the intracellular proteins of the type C human isolated HL23V by radioimmunoprecipitation, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and tryptic peptide analysis. Human and canine cells infected with m7-BaEV and canine thymus cells infected with BILN-BaEV were characterized by identical precursor polyproteins Pr85gag, Pr70-71gag, Pr65gag, and gPr85env. Canine cells infected with 455K-BaEV consistently showed a slightly different pattern of precursor polyproteins. These included Pr85gag, Pr70gag, Pr67gag, and gPR85env. By tryptic digest mapping of peptides containing [3H]leucine, m7-BaEV and 455K-BaEV were shown to be highly related. By comparison, mapping studies showed that BILN-BaEV was less highly related to m7-BaEV than ws 455K-BaEV. Differences in these related BaEV isolates presumably reflected virus-specific differential cleavage of core protein precursors or alterations in polyprotein primary structure or both. Chase-incubated cells infected with BaEV also contained a stable, p28-related polyprotein termed P72gag. This polyprotein migrated upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis slightly slower than the major core protein precursor Pr70-71gag and appeared to arise by posttranslational modification of Pr70-71gag. Immunoprecipitation of extracts of HL23V-infected cells with antisera to simian sarcoma-simian-associated virus proteins and BaEV proteins confirmed that these cells contained two unrelated viral components, one that was similar to m7-BaEV or BILN-BaEV and a second that was related to simian sarcoma-simian-associated virus. Tryptic digest mapping of BaEV and HL23V prcursor polyproteins suggested that the BaEV-like component of HL23V weas more closely related to m7-BaEV than to 455K-BaEV or BILN-BaEV.
- Published
- 1981
- Full Text
- View/download PDF
21. Phenotypic and Genotypic Characterization of Nosocomial Staphylococcus aureusIsolates from Trauma Patients
- Author
-
Na’was, T., Hawwari, A., Hendrix, E., Hebden, J., Edelman, R., Martin, M., Campbell, W., Naso, R., Schwalbe, R., and Fattom, A. I.
- Abstract
ABSTRACTStaphylococcus aureusis a major cause of nosocomial infections. During the period from March 1992 to March 1994, the patients admitted to the intensive care unit of the University of Maryland Shock Trauma Center were monitored for the development ofS. aureusinfections. Among the 776 patients eligible for the study, 60 (7.7%) patients developed 65 incidents of nosocomialS. aureusinfections. Of the clinical isolates, 43.1% possessed a polysaccharide type 5 capsule, 44.6% possessed a type 8 capsule, and the remaining 12.3% had capsules that were not typed by the type 5 or type 8 antibodies. Six antibiogram types were noted among the infection-related isolates, with the majority of the types being resistant only to penicillin and ampicillin. It was noted that the majority of cases of pneumonia were caused by relatively susceptible strains, while resistant strains were isolated from patients with bacteremia and other infections. Only 16 (6.3%) of the isolates were found to be methicillin-resistant S. aureus(MRSA). DNA fingerprinting by pulsed-field gel electrophoresis showed 36 different patterns, with characteristic patterns being found for MRSA strains and the strains with different capsular types. Clonal relationships were established, and the origins of the infection-related isolates in each patient were determined. We conclude that (i) nosocomial infection-related isolates from the shock trauma patients did not belong to a single clone, although the predominance of a methicillin-resistant genotype was noted, (ii) most infection-relatedS. aureusisolates were relatively susceptible to antibiotics, but a MRSA strain was endemic, and (iii) for practical purposes, the combination of the results of capsular and antibiogram typing can be used as a useful epidemiological marker.
- Published
- 1998
- Full Text
- View/download PDF
22. Further studies on the glycosylated gag gene products of Rauscher murine leukemia virus: identification of an N-terminal 45,000-dalton cleavage product
- Author
-
Naso, R B, Stanker, L H, Kopchick, J J, Ng, V L, Karshin, W L, and Arlinghaus, R B
- Abstract
A glycosylated 45,000-Mr protein containing Rauscher murine leukemia virus p15 and p12 antigenic sites and tryptic peptides was identified in Rauscher murine leukemia virus-infected cells. This glycoprotein, termed gP45gag, was also shown to contain a single tryptic peptide also present in gPr80gag and its unglycosylated apoprotein precursor Pr75gag, but lacking in Pr65gag or Pr40gag. The presence of this peptide only in viral precursor proteins containing the so-called leader (L) sequence strongly suggests that gPr45gag is an N-terminal fragment of larger glycosylated gag polyproteins, composed of L sequences in addition to p15 and p12. The kinetics of appearance of radiolabeled gPr45gag and its disappearance during chase-incubation is suggestive of a precursor-like role for this intermediate gene product. An observed 27,000-Mr glycosylated polypeptide, termed gP27gag and containing p15 but not p12, p30, or p10 antigenic determinants, is a candidate cleavage product derived from gPr45gag. These observations suggest that gPr45gag and its putative cleavage product gP27gag represent an authentic pathway for intracellular processing of glycosylated core proteins.
- Published
- 1983
- Full Text
- View/download PDF
23. Polyprotein Precursors to Mouse Mammary Tumor Virus Proteins
- Author
-
Anderson, S. J., Naso, R. B., Davis, J., and Bowen, J. M.
- Abstract
Mouse mammary tumor virus (MMTV) derived from the culture medium of GR cells contained seven proteins, identified as gp55, gp33, p25, pp20, p16, p12, and p10. The major viral phosphoprotein was the 20,000-molecular-weight protein, pp20. Immunoprecipitation of cytoplasmic extracts from pulse-labeled GR cells identified three MMTV gag-specific proteins, termed Pr78gag, Pr110gag, and Pr180gag+. These intracellular polyproteins were precipitable from cytoplasmic extracts by antisera to virions p25 and p12 but not by antisera to gp55. The major intracellular gag-specific precursor polyprotein, Pr78gag, contained antigenic determinants and tryptic peptides characteristic of p25, p12, p10, and presumably pp20. This precursor is presumably derived from nascent chain cleavage or rapid posttranslational cleavage of the larger intracellular precursor-like protein, designated Pr110gag. Pr110gagcontained all but one of the leucine-containing tryptic peptides of Pr78gag, plus several additional peptides. In addition to Pr78gagand Pr110gag, monospecific antisera to virion p12 and p25 were also capable of precipitating from pulse-labeled cells a small amount of a 180,000-molecular-weight precursor-like protein, designated Pr180gag+. This large polyprotein contained nearly all of the leucine-containing tryptic peptides of Pr78gagand Pr110gagplus several additional peptides. By analogy to type C viral systems, Pr180gag+is presumed to represent a gag-polcommon precursor which is the major pathway for synthesis of MMTV polymerase. Immunoprecipitation of cytoplasmic extracts from pulse-labeled cells with antisera to gp55 identified two env-specific proteins, designated gPr76envand gP79env. The major envprecursor, gPr76env, could be labeled with radioactive glucosamine and was shown to contain antigenic determinants and tryptic peptides characteristic of gp55 and gp33. A minor glycoprotein, gP79env, contained both fucose and glucosamine and was precipitable from cytoplasmic extracts with monospecific serum to gp55. It is suggested that gP79envrepresents fucosylated gPr76envwhich is transiently synthesized and cleaved rapidly into gp55 and gp33.
- Published
- 1979
- Full Text
- View/download PDF
24. Characterization of 40,000- and 25,000-dalton intermediate precursors to Rauscher murine leukemia virus gag gene products
- Author
-
Naso, R B, Karshin, W L, Wu, Y H, and Arlinghaus, R B
- Abstract
Under steady-state labeling conditions, Rauscher murine leukemia virus-infected NIH Swiss mouse cells contain at least three major polyproteins derived from the viral gag gene. They have molecular weights of 65,000, 40,000, and 25,000. They have been termed pPr65gag, Pr40gag, and pPr25gag. pPr65gag has been shown by a number of laboratories to be composed of all four core proteins (p15, pp12, p30, and p10). In this paper, Pr40gag was found to contain p30 and p10 antigenic determinants and peptide sequences, whereas pPr25gag was found to contain p15 and pp12. Pr40gag and pPr25gag are rapidly labeled precursor proteins that were detectable early in pulse-chase experiments. Both precursors disappeared during the later stages of the chase period concurrent with the appearance of the mature viral core proteins. pPr65gag and pPr25gag were found to be phosphorylated, pPr25 having a higher specific activity of 32P than pPr65. In spite of this, peptide mapping studies, as well as the identification of the phosphorylated amino acid residues of pPr65, and pPr25, and pp12, indicated that the same sites are phosphorylated regardless of whether the precursors or the mature pp12 are examined.
- Published
- 1979
- Full Text
- View/download PDF
25. Common Precursor for Rauscher Leukemia Virus gp69/71, p15(E), and p12(E)
- Author
-
Karshin, W. L., Arcement, L. J., Naso, R. B., and Arlinghaus, R. B.
- Abstract
Rauscher murine leukemia virus glycoprotein gp69/71 and non-glycosylated p15(E) are synthesized by way of a 90,000-dalton precursor glycoprotein, termed Pr2a+b. Peptide mapping experiments showed that Pr2a+bcontains all the tyrosine-containing tryptic peptides of gp69/71. Two additional tyrosine-containing tryptic peptides in Pr2a+bthat are not detected in gp69/71 are found in p15(E). Thus, gp69/71 and p15(E) peptide sequences account for all the tyrosine tryptic peptides of Pr2a+b. The gene order of the two proteins was determined by pulse-labeling infected cells in the presence and absence of pactamycin at concentrations of the inhibitor that prevent initiation of translation, but not elongation. The gene order was found to be: 2HN-gp69/71-p15(E)-COOH. A newly identified major viral protein, termed p12(E), migrates in sodium dodecyl sulfate-polyacrylamide gels in the “p12” region. It is related to p15(E) as determined by tryptic mapping experiments. p15(E) and p12(E) are not phosphorylated, and both can be separated from phosphoprotein p12 by guanidine hydrochloride-agarose chromatography. p12(E) and p15(E) elute in the void volume fraction, whereas phosphoprotein p12 elutes between p15 and p10. The two p12 proteins can also be separated from each other by two-dimensional gel electrophoresis involving isoelectric focusing in the first dimension and sodium dodecyl sulfate-gel electrophoresis in the second dimension.
- Published
- 1977
- Full Text
- View/download PDF
26. Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection
- Author
-
Smith, R S, Naso, R B, Rosen, J, Whalley, A, Hom, Y L, Hoey, K, Kennedy, C J, McCutchan, J A, Spector, S A, and Richman, D D
- Abstract
Detection of antibodies to human immunodeficiency virus (HIV) by enzyme-linked immunosorbent assay (ELISA) is the accepted method to screen blood products at risk to transmit infection. The presence of antibodies to HIV in 565 serum specimens from 274 patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex, symptomatic and asymptomatic subjects at risk for AIDS, and controls was determined with an ELISA that incorporates synthetic peptides (designated E32/E34) representing sequences in the envelope glycoprotein gp41. Of 105 specimens from patients with AIDS or AIDS-related complex, 3 specimens that were negative by commercially licensed ELISA and immunoblot test were similarly unreactive in the E32/E34 ELISA. For homosexual men with generalized lymphadenopathy, 186 specimens were positive by the E32/E34 ELISA and 63 specimens were negative. In comparison, with the licensed ELISA, 184 of these samples were positive and 65 samples were negative. The two samples that were positive in the E32/E34 ELISA but not the commercial kit were also positive by immunoblotting. Sequential sera from one individual who apparently underwent seroconversion according to the commercial assays were all positive by E32/E34 ELISA and immunoblotting. Thus, the ELISA with synthetic peptides is an extremely sensitive and specific test of antibody response to HIV and has not yet yielded a negative result with a Western blot (immunoblot)-confirmed antibody-positive serum.
- Published
- 1987
- Full Text
- View/download PDF
27. Purification of Large Amounts of Murine Ribonucleic Acid Tumor Viruses Produced in Roller Bottle Cultures
- Author
-
Syrewicz, James J., Naso, R. B., Wang, C. S., and Arlinghaus, Ralph B.
- Abstract
Murine ribonucleic acid tumor viruses and C-type virus particles are produced in relatively large quantities in roller bottle cultures. The viruses present in large volumes of culture fluids can be purified by a simple two-step procedure involving polyethylene glycol precipitation and equilibrium centrifugation in sucrose density gradients.
- Published
- 1972
- Full Text
- View/download PDF
28. A Comparison of the Intracellular Precursor Polyproteins of Simian Sarcoma-associated Virus [SiSV(SiAV)] and Three Human Virus Isolates: HL23V, HEL12V and A1476V
- Author
-
Fuqua, S. A., primary and Naso, R. B., additional
- Published
- 1982
- Full Text
- View/download PDF
29. PI-46.
- Author
-
Lambert, J. R., Duliege, A. M., Stead, R., Wessels, D. H., Pcikup, E. M., Iwashita, J., Leuther, K., Woodburn, K., Schatz, P., and Naso, R.
- Subjects
PHARMACOKINETICS ,ERYTHROPOIESIS ,RETICULOCYTES ,CLINICAL drug trials ,PLACEBOS - Abstract
Background/aim: Hematide is a synthetic, PEGylated, peptidic ESA that binds to and activates the erythropoietin (EPO) receptor. Hematide has comparable in vitro activity to EPO and shows sustained plasma persistence in animal studies. A randomized double-blind placebo controlled, intravenous single dose escalation study was conducted to assess the safety, PK and PD of Hematide in NHVs.Methods: Four cohorts, each with 7 NHVs (5 on active, 2 on placebo) received 0.025, 0.05 or 0.1mg/kg (two cohorts) of Hematide intravenously. Follow-up was at least 28 days. Non-compartmental PK parameters were calculated.Results: Hematide appeared to be safe and well tolerated. Reticulocyte increases were dose proportional (p<0.0001). The 0.1 mg/kg dose produced a clinically and statistically significant increase in hemoglobin (Hgb) from baseline that was sustained for > 1 month. Changes in all other PD parameters were consistent with stimulation of erythropoiesis. Mean C
max ranged from 585 to 2868 ng/mL and the mean half-life ranged from 19 to 23.5 hours (per dose group). First order kinetics were observed at lower drug concentrations only, suggesting saturation of metabolic/elimination processes at higher doses.Conclusion: A single IV injection of Hematide in NHVs was well tolerated and demonstrated potent and sustained dose dependent erythropoietic activity. The sustained increase in Hgb after a single injection support the hypothesis of infrequent administration of Hematide in patients.Clinical Pharmacology & Therapeutics (2005) 79, P19–P19; doi: 10.1016/j.clpt.2005.12.067 [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
30. Biosynthesis of Rauscher leukemia viral proteins
- Author
-
Naso, R
- Published
- 1975
- Full Text
- View/download PDF
31. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.
- Author
-
Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Naso R, Fuller S, Johnson J, Fireman B, and Alcorn H
- Published
- 2002
32. Medien zur Anderswelt
- Author
-
Ballmer, Ariane, Della Casa, Philippe, Ballmer, Ariane, and A. Naso/R. Rollinger/M. Egg
- Subjects
jardin ,[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and Prehistory ,Arme ,tombe ,vallée ,Rhin ,lieu de culte ,ComputingMilieux_MISCELLANEOUS ,Alpes - Published
- 2013
33. Medien zur Anderswelt.: Waffenentäusserungen im Kontext von Gräbern, Horten und Ritualorten im Alpenrheintal
- Author
-
Ballmer, Ariane, Della Casa, Philippe, Celtes et Etrusques : identités, pouvoirs, échanges, Archéologie et Philologie d'Orient et d'Occident (AOROC), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), A. Naso/R. Rollinger/M. Egg, École normale supérieure - Paris (ENS Paris)-École pratique des hautes études (EPHE)-Centre National de la Recherche Scientifique (CNRS)-Paris Sciences et Lettres (PSL)-École normale supérieure - Paris (ENS Paris)-École pratique des hautes études (EPHE)-Centre National de la Recherche Scientifique (CNRS)-Paris Sciences et Lettres (PSL), A. Naso, and Ballmer, Ariane
- Subjects
[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and Prehistory ,jardin ,Arme ,[SHS.ARCHEO]Humanities and Social Sciences/Archaeology and Prehistory ,tombe ,vallée ,Rhin ,lieu de culte ,ComputingMilieux_MISCELLANEOUS ,Alpes - Abstract
International audience
- Published
- 2013
34. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.
- Author
-
Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, and Duliege AM
- Subjects
- Adult, Anemia drug therapy, Antibody Formation, Drug Tolerance, Hemoglobins metabolism, Humans, Male, Peptides immunology, Peptides toxicity, Reticulocytes drug effects, Safety, Erythropoiesis drug effects, Peptides pharmacology
- Abstract
Hematide is an investigational pegylated synthetic peptide that stimulates erythropoiesis in animal models and is being developed for the treatment of anemia associated with chronic renal failure and cancer. This study evaluated the safety and pharmacodynamics of single, intravenous doses (0.025, 0.05, and 0.1 mg/kg) of Hematide in 28 healthy male volunteers. All doses of Hematide were well tolerated, with safety profiles similar to those of placebo. Hematide showed a dose-dependent increase in reticulocytes. The 0.1-mg/kg dose was associated with a statistically significant increase in hemoglobin (Hgb) from baseline compared to the placebo group (13.6 +/- 3.9 g/L [1.36 +/- 0.39 g/dL] versus 3.9 +/- 3.8 g/L [0.39 +/- 0.38 g/dL]; P < .001) that was sustained for longer than 1 month. These results support phase 2 studies in patients with anemia associated with chronic kidney disease or cancer and suggest that Hematide administered as infrequently as once a month may result in a sustained elevation of Hgb levels. (Please note that Hematide is a proposed trade name; the compound does not yet have a nonproprietary name.).
- Published
- 2006
- Full Text
- View/download PDF
35. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.
- Author
-
Fattom A, Fuller S, Propst M, Winston S, Muenz L, He D, Naso R, and Horwith G
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Bacterial blood, Bacterial Capsules immunology, Cross-Over Studies, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoglobulin G blood, Male, Middle Aged, Opsonin Proteins analysis, Placebos, Polysaccharides, Bacterial immunology, Renal Insufficiency therapy, Staphylococcal Vaccines adverse effects, Vaccines, Conjugate administration & dosage, Vaccines, Conjugate adverse effects, Immunization, Secondary adverse effects, Renal Dialysis, Staphylococcal Infections prevention & control, Staphylococcal Vaccines immunology
- Abstract
StaphVAX, an unadjuvanted, bivalent vaccine composed of Staphylococcus aureus (S. aureus) capsular polysaccharides (CPS) types 5 and 8 bound to the mutant non-toxic recombinant Pseudomonas aeruginosa exotoxin A (rEPA) conferred approximately 60% protection for 10 months against bacteremia caused by this pathogen in hemodialysis patients. A protective level of 80 microg/ml was estimated based upon geometric mean (GM) antibody levels at the end of the efficacy period. To extend the duration of protection conferred by StaphVAX in hemodialysis patients, recipients of the vaccine were reinjected in a randomized double-blinded, placebo-controlled study. Vaccinees received StaphVAX and a saline placebo injection 14 days apart according to the randomization schedule. The booster dose of StaphVAX was administered an average of 958 days (753-1167 days) after the first injection. There were no serious adverse reactions. Antibody levels at day 14, 28, 92, and 182 post-injection were measured by ELISA. Maximal levels of IgG anti-CPS were observed at the 28-day interval. For type 5, GM antibody levels increased from 73 microg/ml at day 0 to 162 microg/ml (P < 0.001) and for type 8 from 59 microg/ml to 133 microg/ml (P < 0.001). Anti-CPS antibody levels of approximately 80 microg/ml to type 5 and type 8 were achieved in 72.4 and 74.3% of vaccinees, respectively. There was excellent correlation between the level of anti-CPS and opsonic titer (r = 0.93). Moreover, the decline of anti-CPS antibody levels at six months was significantly less rapid than that observed from the first immunization (P < 0.001). We conclude that a booster immunization to maintain protective levels of specific antibodies for an extended period of time is feasible for patients at continuous risk for S. aureus bacteremia.
- Published
- 2004
- Full Text
- View/download PDF
36. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials.
- Author
-
Fattom AI, Horwith G, Fuller S, Propst M, and Naso R
- Subjects
- Animals, Clinical Trials, Phase III as Topic, Humans, Staphylococcal Infections immunology, Staphylococcal Vaccines immunology, Vaccines, Conjugate, Staphylococcal Infections prevention & control, Staphylococcal Vaccines therapeutic use
- Abstract
Staphylococcus aureus is the most common nosocomial pathogen and is responsible for approximately one-third of hospital-acquired bacteremias. The emergence of strains with multidrug resistance, including resistance to vancomycin, the antibiotic of last resort, presents the medical community with a major public health problem. Alternative therapies, including immunotherapy, have been in development for several decades. The discovery of S. aureus capsular polysaccharides from clinical isolates, and their importance to pathogenicity via antiphagocytic activity, opened a new window of opportunity for development of vaccines and immunotherapy against this pathogen. A conjugate vaccine, StaphVAX that includes the two most prevalent capsular polysaccharides, types 5 and 8, coupled to a carrier protein efficient in promoting a Th2 response, was developed. In a recent phase III clinical study in hemodialysis patients, StaphVAX was shown to prevent S. aureus bacteremia for up to 10 months following a single immunization. The history, epidemiology, serology, and development of StaphVAX, including preclinical and clinical studies demonstrating efficacy are described in this review.
- Published
- 2004
- Full Text
- View/download PDF
37. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome.
- Author
-
Malin DH, Lake JR, Lin A, Saldaña M, Balch L, Irvin ML, Chandrasekara H, Alvarado CL, Hieda Y, Keyler DE, Pentel PR, Ennifar S, Basham LE, Naso R, and Fattom A
- Subjects
- Analysis of Variance, Animals, Antibodies chemistry, Brain metabolism, Drug Implants, Immunoglobulin G chemistry, Immunoglobulin G immunology, Injections, Subcutaneous, Male, Nicotine administration & dosage, Nicotinic Agonists administration & dosage, Protein Binding, Rats, Rats, Sprague-Dawley, Immunization, Passive psychology, Nicotine immunology, Nicotine therapeutic use, Nicotinic Agonists immunology, Nicotinic Agonists therapeutic use, Substance Withdrawal Syndrome psychology
- Abstract
Passive immunization against nicotine interferes with its locomotor and pressor effects. The current study determined whether immunization could prevent another nicotine action: the reversal of nicotine abstinence syndrome. IgG containing 4.4-5.6% nicotine-specific antibody was isolated from rabbits immunized with 3'-amino-methyl-nicotine conjugated to a carrier protein. Twenty rats were rendered dependent by 7 days of subcutaneous infusion of 3.15 mg/kg/day nicotine (expressed as the base). Upon termination of nicotine infusion, each rat was injected intraperitoneally with 150 mg of IgG from normal serum (n=13) or from nicotine antiserum (n=7). Twenty-two and one-half hours later, all rats were observed over 15 min for baseline nicotine abstinence signs. Two and one-half hours after baseline observations, seven of the 13 rats pretreated with control IgG and all seven rats pretreated with nicotine-specific IgG were then challenged by 0.12 mg/kg (sc) nicotine. The remaining six rats pretreated with control IgG were challenged with saline alone. All rats were then observed again for abstinence signs. Nicotine injection caused significantly less reduction of abstinence signs in the immunized rats. The nicotine effect in immunized rats was comparable to the saline effect in nonimmunized rats. Immunization also significantly reduced free serum nicotine concentration and nicotine distribution to the brain. These results raise the possibility that immunization might prevent nicotine consumption from relieving the discomforts of smoking cessation.
- Published
- 2001
- Full Text
- View/download PDF
38. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats.
- Author
-
Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, Naso R, and Fattom A
- Subjects
- Animals, Blood Pressure drug effects, Immunization, Passive, Immunoglobulin G immunology, Motor Activity drug effects, Nicotine pharmacokinetics, Nicotine pharmacology, Rabbits, Rats, Rats, Sprague-Dawley, Vaccination, Brain metabolism, Nicotine immunology, Vaccines, Conjugate immunology
- Abstract
Vaccination of animals to elicit drug-specific antibodies, or the passive transfer of such antibodies from other animals, can reduce the behavioral effects of drugs such as cocaine and heroin. To study the potential application of this approach to treating nicotine dependence, IgG was isolated from rabbits immunized with a nicotine-protein conjugate vaccine. Anesthetized rats received immune IgG containing nicotine-specific antibodies (Nic-IgG) or control-IgG i.v.. Thirty minutes later, rats received nicotine at 0.03 mg/kg i.v., equivalent on an mg/kg basis to the nicotine intake from two cigarettes by a smoker. Compared to control-IgG, Nic-IgG reduced the brain nicotine concentration in a dose-related manner (65% reduction at the highest IgG dose). Pretreatment with Nic-IgG also reduced the distribution to brain of five repeated doses of nicotine (equivalent to the nicotine intake from 10 cigarettes) administered over 80 min. To study blood pressure effects, rats received control-IgG or Nic-IgG 1 day prior to administering nicotine. Nicotine-induced systolic blood pressure increases were attenuated by Nic-IgG in a dose-related manner, and were almost completely blocked by the highest Nic-IgG dose. Pretreatment with Nic-IgG also completely prevented the nicotine-induced stimulation of locomotor activity observed in rats receiving control-IgG. Nic-IgG did not prevent locomotor activation from cocaine, demonstrating its specificity for nicotine. These data demonstrate that the administration of nicotine-specific antibodies can reduce or prevent some of the pharmacokinetic, cardiovascular, and behavioral consequences of nicotine in rats. Effects were observed at nicotine doses and nicotine serum concentrations equal to or exceeding those typically associated with nicotine exposure in cigarette smokers. A potential role for immunization in the treatment of nicotine dependence is suggested.
- Published
- 2000
- Full Text
- View/download PDF
39. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines.
- Author
-
Fattom A, Cho YH, Chu C, Fuller S, Fries L, and Naso R
- Subjects
- Animals, Antibodies, Bacterial blood, Epitopes administration & dosage, Female, Immune Tolerance, Injections, Subcutaneous, Mice, Mice, Inbred ICR, Staphylococcus aureus immunology, Vaccines, Combined administration & dosage, Vaccines, Combined immunology, Vaccines, Conjugate administration & dosage, Vaccines, Conjugate immunology, Bacterial Vaccines administration & dosage, Bacterial Vaccines immunology, Polysaccharides, Bacterial administration & dosage, Polysaccharides, Bacterial immunology
- Abstract
Capsular polysaccharide (CP) conjugate vaccines targeting a variety of bacterial infections are currently under development and clinical evaluation. The inclusion of multiple CP serotypes combined in a single injection is an important maneuver being evaluated. The combination of CP conjugate vaccines into a single multivalent injection may result in competition among the different components and adversely affect the immunogenicity of any individual conjugate. We observed a reduction of 30-90% in antibody responses to several serotypes in mice when immunogenicity of a 12-valent Escherichia coli (E. coli) lipopolysaccharide (LPS) conjugate vaccine was compared to the immunogenicity of each monovalent vaccine evaluated separately. A reduction of 30% was observed in the Staphylococcus aureus (S. aureus) type 8 CP antibodies when a type 8-rEPA conjugate was combined with a type 5-rEPA conjugate. S. aureus types 5 and 8-rEPA conjugates were combined with 100 micrograms of either rEPA (homologous) or diphtheria toxoid (DT) (heterologous) carrier proteins, and evaluated in rEPA or DT primed mice. The addition of the homologous protein resulted in a 64% reduction in type 5 CP antibodies. The heterologous protein did not affect the immunogenicity of the type 5. We postulate that the free protein competed with the conjugate and recruited most of the rEPA primed T cells. In the case of the DT conjugates, the DT targeted different populations of the T cells, thus interference was not observed. These data suggested that the epitopic load rather than the antigenic load at the site of injection caused reduced immunogenicity of the conjugates. We theorize that individual components of multivalent CP vaccines conjugated to the same carrier proteins would compete for a limited number of specific carrier protein primed T cells. This would result in one or more components being unavailable in eliciting a sufficient immune response. The use of multiple carrier proteins should be considered as an approach to reduce interference when multivalent conjugate vaccines are to be formulated into a single injection.
- Published
- 1999
- Full Text
- View/download PDF
40. Phenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients.
- Author
-
Na'was T, Hawwari A, Hendrix E, Hebden J, Edelman R, Martin M, Campbell W, Naso R, Schwalbe R, and Fattom AI
- Subjects
- Adolescent, Adult, Aged, Ampicillin Resistance genetics, Antibodies, Bacterial analysis, Antibodies, Bacterial immunology, Bacteremia epidemiology, Bacteremia microbiology, Child, Cross Infection microbiology, Electrophoresis, Gel, Pulsed-Field, Female, Humans, Intensive Care Units, Male, Maryland epidemiology, Microbial Sensitivity Tests, Middle Aged, Molecular Epidemiology, Penicillin Resistance genetics, Pneumonia, Bacterial epidemiology, Pneumonia, Bacterial microbiology, Polymorphism, Genetic, Polysaccharides, Bacterial analysis, Trauma Centers, Cross Infection epidemiology, DNA, Bacterial analysis, Staphylococcal Infections epidemiology, Staphylococcal Infections microbiology, Staphylococcus aureus genetics, Staphylococcus aureus isolation & purification
- Abstract
Staphylococcus aureus is a major cause of nosocomial infections. During the period from March 1992 to March 1994, the patients admitted to the intensive care unit of the University of Maryland Shock Trauma Center were monitored for the development of S. aureus infections. Among the 776 patients eligible for the study, 60 (7.7%) patients developed 65 incidents of nosocomial S. aureus infections. Of the clinical isolates, 43.1% possessed a polysaccharide type 5 capsule, 44.6% possessed a type 8 capsule, and the remaining 12.3% had capsules that were not typed by the type 5 or type 8 antibodies. Six antibiogram types were noted among the infection-related isolates, with the majority of the types being resistant only to penicillin and ampicillin. It was noted that the majority of cases of pneumonia were caused by relatively susceptible strains, while resistant strains were isolated from patients with bacteremia and other infections. Only 16 (6.3%) of the isolates were found to be methicillin-resistant S. aureus (MRSA). DNA fingerprinting by pulsed-field gel electrophoresis showed 36 different patterns, with characteristic patterns being found for MRSA strains and the strains with different capsular types. Clonal relationships were established, and the origins of the infection-related isolates in each patient were determined. We conclude that (i) nosocomial infection-related isolates from the shock trauma patients did not belong to a single clone, although the predominance of a methicillin-resistant genotype was noted, (ii) most infection-related S. aureus isolates were relatively susceptible to antibiotics, but a MRSA strain was endemic, and (iii) for practical purposes, the combination of the results of capsular and antibiogram typing can be used as a useful epidemiological marker.
- Published
- 1998
- Full Text
- View/download PDF
41. Staphylococcus aureus vaccination for dialysis patients--an update.
- Author
-
Fattom AI and Naso R
- Subjects
- Animals, Bacterial Vaccines, Humans, Kidney Failure, Chronic immunology, Staphylococcus aureus, Renal Replacement Therapy, Staphylococcal Infections prevention & control, Vaccination
- Abstract
Staphylococcus aureus infections are a major cause in both hemodialysis and peritoneal dialysis patients. The availability of a safe and effective protective vaccine would be of great benefit to these patients, but attempts at using vaccines consisting of inactivated whole cells have been unsuccessful. This article discusses an alternate approach to S. aureus vaccine design using a capsular polysaccharide conjugate and preliminary results in hemodialysis and peritoneal patients.
- Published
- 1996
- Full Text
- View/download PDF
42. Staphylococcal vaccines: a realistic dream.
- Author
-
Fattom AI and Naso R
- Subjects
- Animals, Bacterial Capsules immunology, Disease Models, Animal, Humans, Immunocompromised Host, Infant, Newborn, Mice, Mice, Inbred BALB C, Vaccines, Conjugate, Staphylococcal Vaccines immunology, Staphylococcus aureus immunology
- Abstract
Staphylococcus aureus, especially multidrug resistant strains, continues to be a leading cause of serious nosocomial infections. In spite of the debate among investigators in the field, the discovery of serologically distinct capsular polysaccharides on the surface of clinical isolates has renewed the prospects for development of vaccines and passive protective immunity against S. aureus infections. Capsular polysaccharide conjugate vaccines have now been produced and proven to be safe and immunogenic in both healthy and in a significant percentage of immunocompromised patients. Antibodies generated in humans against these vaccines have been shown to mediate type-specific opsonophagocytosis, and to protect animals against lethal challenge with the appropriate S. aureus isolate.
- Published
- 1996
- Full Text
- View/download PDF
43. Polysaccharide conjugate vaccines for the prevention of gram-positive bacterial infections.
- Author
-
Naso R and Fattom A
- Subjects
- Animals, Carbohydrate Sequence, Gram-Positive Bacteria immunology, Gram-Positive Bacterial Infections immunology, Humans, Immunization, Passive, Mice, Molecular Sequence Data, Oligosaccharides chemistry, Polysaccharides, Bacterial chemistry, Polysaccharides, Bacterial immunology, Staphylococcal Infections immunology, Staphylococcal Infections prevention & control, Staphylococcus aureus immunology, Bacterial Vaccines toxicity, Gram-Positive Bacterial Infections prevention & control, Vaccines, Conjugate toxicity
- Published
- 1996
- Full Text
- View/download PDF
44. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides.
- Author
-
Fattom A, Li X, Cho YH, Burns A, Hawwari A, Shepherd SE, Coughlin R, Winston S, and Naso R
- Subjects
- Animals, Antibodies, Bacterial blood, Bacterial Capsules immunology, Bacterial Proteins pharmacology, Diphtheria Toxoid pharmacology, Exotoxins pharmacology, Female, Immunoglobulin G blood, Mice, Mice, Inbred ICR, Recombinant Proteins pharmacology, Vaccines, Conjugate pharmacology, Pseudomonas aeruginosa Exotoxin A, ADP Ribose Transferases, Adjuvants, Immunologic pharmacology, Bacterial Toxins, Bacterial Vaccines pharmacology, Carrier Proteins pharmacology, Polysaccharides, Bacterial immunology, Staphylococcus aureus immunology, Virulence Factors
- Abstract
Conjugate vaccines were prepared with S. aureus type 8 capsular polysaccharide (CP) using three carrier proteins: Pseudomonas aeruginosa exotoxin A (ETA), a non-toxic recombinant ETA (rEPA), and diphtheria toxoid (DTd). Adipic acid dihydrazide (ADH) or N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) was used as a spacer to link the CP to carrier protein. All conjugates gave a high immune response with a boost after the second immunization. Conjugates prepared with ADH gave higher antibody titers than conjugates prepared with SPDP. IgG1 was the primary subclass elicited by all conjugates regardless of the carrier protein or the conjugation method used to prepare the vaccines. The non-immunogenic CP and the conjugates were formulated with either monophosphoryl lipid A (MPL), QS21, or in Novasomes and evaluated in mice. While the adjuvants failed to improve the immunogenicity of the nonconjugated CP, a more than fivefold increase in the antibody levels was observed when these adjuvants were used with the conjugates. Significant rises in IgG2b and IgG3 were observed with all formulations. The enhancement of the immunogenicity and the IgG subclass shift, as seen with some adjuvants, may prove to be important in immunocompromised patients.
- Published
- 1995
- Full Text
- View/download PDF
45. Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent.
- Author
-
Corbo DC, Suddith RL, Sharma B, and Naso RB
- Subjects
- Animals, Blotting, Western, Drug Incompatibility, Drug Stability, Erythrocytes metabolism, Erythropoietin blood, Erythropoietin pharmacology, Iron blood, Mice, Preservatives, Pharmaceutical, Radioimmunoassay, Recombinant Proteins blood, Recombinant Proteins chemistry, Recombinant Proteins pharmacology, Sodium Chloride pharmacology, Erythropoietin chemistry
- Abstract
The stability, potency, and preservative effectiveness of two dilutions of epoetin alfa containing a bacteriostatic diluent were studied. Epoetin alfa 10,000 units/mL in single-use vials was diluted 1:1 and 1:1.5 with bacteriostatic 0.9% sodium chloride injection. USP tests of preservative effectiveness were performed on samples from two batches each of the 1:1 and the 1:1.5 dilutions. Appearance assessment, Western blot analysis, radioimmunoassay, and bioassay were used to determine the stability or potency of samples from three batches of each dilution that were stored at 5 degrees C or at 30 degrees C for 12 weeks. Both batches of the 1:1.5 dilution (epoetin alfa 4,000 units/mL with 0.54% benzyl alcohol) met the USP criteria for preserved solutions, while one batch of the 1:1 dilution (epoetin alfa 5,000 units/mL with 0.45% benzyl alcohol) did not. Epoetin alfa 10,000 units/mL diluted either 1:1 or 1:1.5 with bacteriostatic 0.9% sodium chloride injection and stored at 5 degrees C or at 30 degrees C remained stable and potent for 12 weeks. The addition of 1.5 mL of bacteriostatic 0.9% sodium chloride injection to a vial containing 1 mL of epoetin alfa 10,000 units/mL makes a solution of epoetin alfa 4,000 units/mL that meets the USP criteria for preservative effectiveness and remains stable and potent for 12 weeks at 5 degrees C.
- Published
- 1992
46. Cloning of the amino terminal nucleotides of the antigen I/II of Streptococcus sobrinus and the immune responses to the corresponding synthetic peptides.
- Author
-
Staffileno LK, Hendricks M, LaPolla R, Bohart C, Van Hook P, Rosen JI, Warner J, Hoey K, Wegemer D, and Naso RB
- Subjects
- Amino Acid Sequence, Animals, Antibodies, Bacterial biosynthesis, Antigens, Bacterial immunology, Antigens, Surface genetics, Antigens, Surface immunology, Base Sequence, Cloning, Molecular, DNA, Bacterial genetics, DNA, Bacterial isolation & purification, Immunization, Lymphocyte Activation, Mice, Mice, Inbred BALB C, Mice, Inbred C3H, Mice, Inbred Strains, Molecular Sequence Data, Streptococcus genetics, Streptococcus mutans genetics, Streptococcus mutans immunology, Vaccines, Synthetic chemical synthesis, Vaccines, Synthetic immunology, Antigens, Bacterial genetics, Bacterial Proteins genetics, Membrane Glycoproteins, Nucleotides genetics, Streptococcus immunology
- Abstract
A portion of the antigen I/II (spaA, B, P1) gene of Streptococcus sobrinus 6715, containing the coding sequence for the amino terminal 684 amino acids of the protein, was cloned in bacteriophage lambda GT10. Selection was by immunological detection using a polyclonal antiserum to the antigen I/II from Strep. mutans. From the amino acid sequence, peptides were synthesized, 15 amino acids in length, that covered the entire sequence. In total, 260 synthetic peptides were synthesized and evaluated for their immunogenicity in Balb/C mice. Thirty-nine peptides were immunogenic, without carrier, and the antisera generated were tested for their ability to bind cells of Strep. mutans and Strep. sobrinus in a solid-phase assay. Antisera corresponding to peptides from five regions on the I/II molecule bound cells of both bacterial species. These peptides were then evaluated for their ability to stimulate in vitro murine lymphocyte proliferation, after in vivo immunization with Strep. sobrinus cells. Two of the peptides were capable of stimulating proliferation, as determined by incorporation of [3H]-thymidine into murine lymph node cells. The sequences of these 5 peptides were then compared to sequences found in the antigen I/II from Strep. mutans (Kelly et al., 1989). As expected, there was considerable homology between the cross-reactive peptides synthesized and the analogous region from Strep. mutans. This homology was not usually contiguous and suggests that the antibodies bind a face of antigen I/II that is in an alpha-helical conformation.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1990
- Full Text
- View/download PDF
47. Proteins of Rauscher murine leukemia virus: resolution of a 70,000-dalton, Nonglycosylated polypeptide containing p30 peptide sequences.
- Author
-
Jamjoom G, Karshin WL, Naso RB, Arcement LJ, and Arlinghaus RB
- Subjects
- Amino Acids metabolism, Base Sequence, Carbon Radioisotopes, Cell Line, Fucose metabolism, Glucosamine metabolism, Glycoproteins analysis, Methionine metabolism, Molecular Weight, Rauscher Virus metabolism, Sulfur Radioisotopes, Viral Proteins biosynthesis, Peptides analysis, Rauscher Virus analysis, Viral Proteins analysis
- Published
- 1975
- Full Text
- View/download PDF
48. The cell-free translation of Rauscher leukemia virus RNA into high molecular weight polypeptides.
- Author
-
Naso RB, Arcement LJ, Wood G, Saunders TE, and Arlinghaus RB
- Subjects
- Amino Acids metabolism, Animals, Cell-Free System, Electrophoresis, Polyacrylamide Gel, Molecular Weight, Precipitin Tests, Rabbits immunology, Reticulocytes metabolism, Protein Biosynthesis, RNA, Messenger metabolism, RNA, Neoplasm metabolism, Rauscher Virus metabolism, Viral Proteins biosynthesis
- Abstract
Rauscher leukemia virus (RLV) 65-S RNA, 35-S mengovirus RNA and reticulocyte A-rich RNA each stimulated cell-free protein synthesis in a JLS-V5 cell derived S-30 system. rRNA, however, was not stimulatory in this system. Of the stimulated protein products only those synthesized in response to added RLV RNA were immune-precipitable with anti-RLV rabbit serum. Furthermore, cell-free incubations with pactamycin at a concentration which specifically inhibits initiation and not elongation prevented the stimulation of amino acid incorporation in response to added RLV RNA. Analysis of the polypeptides synthesized by the cell-free system in response to reticulocyte A-rich RNA, showed them to be globin-like and, therefore, also mRNA specific. The RLV RNA-directed product included at least two classes of polypeptides (mol. wts of 140 000-185 000 and 50 000-75 000) both of which were larger than the group specific polypeptides of mature virions. None of the internal structural polypeptides of mature virions were synthesized in response to RLV RNA. The large molecular weight, viral-specific polypeptides are candidate precursor polyproteins which may represent the translational products of a polycistronic mRNA with a single initiation site.
- Published
- 1975
- Full Text
- View/download PDF
49. Biosynthesis of Rauscher leukemia viral proteins: presence of p30 and envelope p15 sequences in precursor polypeptides.
- Author
-
Arcement LJ, Karshin WL, Naso RB, Jamjoom G, and Arlinghaus RB
- Subjects
- Base Sequence, Cell Line, Cycloheximide pharmacology, Immune Sera, Peptide Biosynthesis, Protein Precursors biosynthesis, Peptides metabolism, Protein Precursors metabolism, Rauscher Virus metabolism, Viral Proteins biosynthesis
- Published
- 1976
- Full Text
- View/download PDF
50. Further characterization of intracellular precursor polyproteins of Rauscher leukemia virus.
- Author
-
Jamjoom GA, Naso RB, and Arlinghaus RB
- Subjects
- Amino Acid Chloromethyl Ketones pharmacology, Antigens, Viral, Canavanine pharmacology, Cell Line, Epitopes, Immunoassay, Molecular Weight, Pactamycin pharmacology, RNA-Directed DNA Polymerase, Tosyllysine Chloromethyl Ketone pharmacology, Tosylphenylalanyl Chloromethyl Ketone pharmacology, Viral Proteins immunology, Protein Biosynthesis, Rauscher Virus metabolism, Viral Proteins biosynthesis
- Published
- 1977
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.